David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation
David Stegner, Professor of Vascular Imaging at the Julius Maximilians University of Würzburg, reposted from Boehringer Ingelheim on LinkedIn:
”A strong example of how fundamental platelet research can translate into therapeutic innovation.
Work from University Hospital of Würzburg has identified GPVI as a key driver of thrombo-inflammation in acute ischemic stroke, directly linking platelet biology to clinical outcome.
The collaboration between Boehringer Ingelheim and Emfret Analytics now advances this concept toward clinical application.
Targeting GPVI offers a compelling strategy: inhibiting pathological platelet activation while preserving hemostasis – a critical requirement in stroke therapy.
For the field, this marks an important translational milestone.
For patients, it highlights the potential to improve outcomes beyond current standard-of-care.”
Quoting Boehringer Ingelheim‘s post:
”NEWS: We are collaborating with Emfret Analytics to advance a potential first‑in‑class antibody‑based approach for acute ischemic stroke.
For decades, we have helped transform stroke care.
By targeting the platelet receptor GPVI, this new approach aims to inhibit thrombus formation and growth while maintaining normal hemostasis – designed to complement standard‑of‑care therapies and further improve patient outcomes.”
Stay updated with Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque